Pharmazz

Saving Lives Through Innovation

[Sunil Gulati @gulatisunil]

https://t.co/NX2e4dKfQT

[Pharmazz @Pharmazz]

Our CEO, Dr. Anil Gulati, will be present at the 2023 Critical Care Congress in San Francisco on Sunday, 1/22 at 10:15am PST in Exhibit Hall-RST 11. We will feature positive data from the Ph. III sovateltide study, a potential treatment for cerebral ischemic #stroke.

#SCCM2023

[Pharmazz @Pharmazz]

This #ADM2022, we want to highlight our work targeting diabetic ketoacidosis (DKA). Our experimental studies have shown that PMZ-2123 prevents the development of neurological complications in DKA and cerebral edema in an animal model with DKA.
Learn more: https://t.co/7MRZhQ46nk

[Pharmazz @Pharmazz]

We’re pleased to announce the full data on our positive Ph. 3 trial on sovateltide as a treatment for acute cerebral ischemic stroke. The study was statistically significant, had meaningful improvements in multiple neurological outcomes & well tolerated.

https://t.co/x9alY5PKgN

[Pharmazz @Pharmazz]

We’re pleased to announce the full data on our positive Ph. 3 trial on sovateltide as a treatment for acute cerebral ischemic stroke. The study was statistically significant, had meaningful improvements in multiple neurological outcomes & well tolerated.

https://t.co/x9alY5PKgN

[Pharmazz @Pharmazz]

#WorldStrokeDay is special to our team because we’re dedicated to developing a safe & effective #stroke treatment. Today we presented positive data on our Phase III clinical trial of sovateltide for the treatment of acute cerebral ischemic stroke at the #WSC.

[Pharmazz @Pharmazz]

Our CEO, Dr. Anil Gulati, will present at the World Stroke Congress in Singapore from Oct. 26-29. Dr. Gulati is excited to share detailed data during two presentations on sovateltide, featuring positive data from our Ph. 3 acute ischemic stroke trial. #WSC2022

[Pharmazz @Pharmazz]

In 2019, an estimated 374 children were injured every day in car crashes. When accidents happen, severe fluid and blood loss can cause hypovolemic shock. To combat this, we’re developing centhaquine, a novel, first-in-class resuscitative agent.

[Pharmazz @Pharmazz]

Sepsis is the leading cause of death in U.S. hospitals, a reality that Pharmazz is working to change with the clinical study of centhaquine to treat septic shock which often develops in sepsis patients. #SepsisAwarenessMonth #SAM2022

Learn more: https://t.co/yy7qKVSzpW

[Pharmazz @Pharmazz]

Today, our CEO, Dr. Anil Gulati, will present at the Military Health System Research Symposium (MHSRS) at 10am EDT. Dr. Gulati will discuss pos. data from the Ph. III study of centhaquine as a resuscitative agent in hypovolemic shock patients.

Learn more: https://t.co/ZtzbxtkpxA

[Pharmazz @Pharmazz]

The @CDSCO_INDIA_INF has given us clearance of our IND application for a Phase II clinical trial of #solvateltide to treat hypoxic-ischemic encephalopathy (HIE) in neonates.

Learn more at: https://t.co/Iv7rtXtGEO

#Clinicaltrial #PhaseII #NTC05514340

[Pharmazz @Pharmazz]

This month is National Traffic Awareness Month to highlight the importance of following traffic safety laws. Car wrecks are most commonly associated with hypovolemic shock which we are developing a treatment for in a Phase 3 clinical trial of #centhaquine.

[Pharmazz @Pharmazz]

Happy #Pride Month! Thank you to the members of the #LGBTQ+ community who have aided in the advancements of the medical field, especially within critical care and hospital settings where we are currently developing novel therapeutics.

[Pharmazz @Pharmazz]

Happy #MensHealthMonth! The @CDC states that on average in the US, men die at higher rates from three leading causes: heart disease, cancer & unintentional injuries. We’re working to progress our pipeline of critical care therapeutics which target these areas & aim to save lives.

[Pharmazz @Pharmazz]

This #CancerSurvivorMonth, we would like to acknowledge those who have battled with cancer and celebrate their milestones. #CelebrateSurvivorship

[Pharmazz @Pharmazz]

May is #NationalUrgentCareAwarenessMonth where we celebrate the exceptional contributions of professionals in urgent care and on-demand medicine. We hope to leave our mark on this industry with our pipeline of critical care therapeutics.

[Pharmazz @Pharmazz]

There is a desperate need for more stroke treatment options. We could not be prouder to have announced positive results from our Phase III clinical trial for #sovateltide as a treatment for acute ischemic stroke during #NationalStrokeAwarenessMonth.

See: https://t.co/dkVUMdRVWb

[Pharmazz @Pharmazz]

Today we announced positive results from our Phase III clinical trial evaluating #sovateltide as a treatment for acute ischemic #stroke. Our data is being submitted to the @CDSCO_INDIA_INF for marketing authorization.

See: https://t.co/dkVUMe9xkL

[Pharmazz @Pharmazz]

Approximately 40% of trauma-related deaths worldwide are due to bleeding or its consequences. We have developed #centhaquine, a novel, first-in-class resuscitative agent for the treatment of hypovolemic shock to help lower this statistic.

#StopTheBleedDay

[Pharmazz @Pharmazz]

This #EMSWeek, all of us at Pharmazz, Inc. would like to thank EMS professionals for dedicating their lives to helping others during their time of need. We stand with you and hope that our pipeline of critical care medicines will help when #RisingtotheChallenge to save lives.